Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)

被引：21

作者：

Mercer, Swati P. ^{[1
]}

Roecker, Anthony J. ^{[1
]}

Garson, Susan ^{[2
]}

Reiss, Duane R. ^{[2
]}

Harrell, C. Meacham ^{[2
]}

Murphy, Kathy L. ^{[2
]}

Bruno, Joseph G. ^{[4
]}

Bednar, Rodney A. ^{[4
]}

Lemaire, Wei ^{[2
]}

Cui, Donghui ^{[3
]}

Cabalu, Tamara D. ^{[3
]}

Tang, Cuyue ^{[3
]}

Prueksaritanont, Thomayant ^{[3
]}

Hartman, George D. ^{[1
]}

Young, Steven D. ^{[1
]}

Winrow, Christopher J. ^{[2
]}

Renger, John J. ^{[2
]}

Coleman, Paul J. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA

[2] Merck Res Labs, Dept Neurosci, West Point, PA 19486 USA

[3] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA

[4] Merck Res Labs, West Point Facil Automat & Screening WP FAST, West Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 24期

关键词：

Orexin receptor antagonists; Selective orexin-2 receptor antagonists; Insomnia; Hypocretin; Rat sleep EEG; P-GLYCOPROTEIN; POTENT; SLEEP; PROMOTION;

D O I：

10.1016/j.bmcl.2013.10.045

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The orexin (or hypocretin) system has been identified as a novel target for the treatment of insomnia due to the wealth of biological and genetic data discovered over the past decade. Recently, clinical proof-of-concept was achieved for the treatment of primary insomnia using dual (OX1R/OX2R) orexin receptor antagonists. However, elucidation of the pharmacology associated with selective orexin-2 receptor antagonists (2-SORAs) has been hampered by the lack of orally bioavailable, highly selective small molecule probes. Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described. A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：6620 / 6624

页数：5

共 50 条

[1] Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists
Fujimoto, Tatsuhiko
Tomata, Yoshihide
Kunitomo, Jun
Hirozane, Mariko
Marui, Shogo
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (21) : 6409 - 6413
[2] Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists
Skudlarek, Jason W.
DiMarco, Christina N.
Babaoglu, Kerim
Roecker, Anthony J.
Bruno, Joseph G.
Pausch, Mark A.
O'Brien, Julie A.
Cabalu, Tamara D.
Stevens, Joanne
Brunner, Joseph
Tannenbaum, Pamela L.
Wuelfing, W. Peter
Garson, Susan L.
Fox, Steven V.
Savitz, Alan T.
Harrell, Charles M.
Gotter, Anthony L.
Winrow, Christopher J.
Renger, John J.
Kuduk, Scott D.
Coleman, Paul J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (06) : 1364 - 1370
[3] Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists
Fujimoto, Tatsuhiko
Kunitomo, Jun
Tomata, Yoshihide
Nishiyama, Keiji
Nakashima, Masato
Hirozane, Mariko
Yoshikubo, Shin-ichi
Hirai, Keisuke
Marui, Shogo
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (21) : 6414 - 6416
[4] Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant
Raheem, Izzat T.
Breslin, Michael J.
Bruno, Joseph
Cabalu, Tamara D.
Cooke, Andrew
Cox, Christopher D.
Cui, Donghui
Garson, Susan
Gotter, Anthony L.
Fox, Steven V.
Harrell, C. Meacham
Kuduk, Scott D.
Lemaire, Wei
Prueksaritanont, Thomayant
Renger, John J.
Stump, Craig
Tannenbaum, Pamela L.
Williams, Peter D.
Winrow, Christopher J.
Coleman, Paul J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 444 - 450
[5] Selective Orexin-2 Receptor Antagonism as Adjunctive Therapy for Insomnia in Depression
Lovenberg, Timothy
Shelton, Jonathan
Yun, Sujin
Bonaventure, Pascal
Shireman, Brock
Dugovic, Christine
NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S543 - S544
[6] Localization of orexin B and orexin-2 receptor in the rat epididymis
Liguori, Giovanna
Tafuri, Simona
Miyoshi, Chika
Yanagisawa, Masashi
Squillacioti, Caterina
De Pasquale, Valeria
Mirabella, Nicola
Vittoria, Alfredo
Costagliola, Anna
ACTA HISTOCHEMICA, 2018, 120 (03) : 292 - 297
[7] Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology
Stump, Craig A.
Cooke, Andrew J.
Bruno, Joseph
Cabalu, Tamara D.
Gotter, Anthony L.
Harell, C. Meacham
Kuduk, Scott D.
McDonald, Terrence P.
O'Brien, Julie
Renger, John J.
Williams, Peter D.
Winrow, Christopher J.
Coleman, Paul J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (23) : 5809 - 5814
[8] Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements
Roecker, Anthony J.
Mercer, Swati P.
Bergman, Jeffrey M.
Gilbert, Kevin F.
Kuduk, Scott D.
Harrell, C. Meacham
Garson, Susan L.
Fox, Steven V.
Gotter, Anthony L.
Tannenbaum, Pamela L.
Prueksaritanont, Thomayant
Cabalu, Tamara D.
Cui, Donghui
Lemaire, Wei
Winrow, Christopher J.
Renger, John J.
Coleman, Paul J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (21) : 4992 - 4999
[9] Discovery of JNJ-42847922, a selective orexin-2 antagonist for the treatment of insomnia disorder
Letavic, Michael
Bonaventure, Pascal
Ly, Kiev
Aguilar, Zuleima
Aluisio, Leah
Carruthers, Nicholas
Chaplan, Sandra
Dugovic, Christine
Halter, Robin
Koudriakova, Tatiana
Lord, Brian
Lovenberg, Timothy
Kramer, Michelle
Morton, Kirsten
Ndifor, Anthony
Rizzolio, Michele
Shah, Chandra
Shelton, Jonathan
Shoblock, James
Sutton, Steven
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
[10] Synthesis of (3,4-dimethoxyphenoxy)alkylamino acetamides as orexin-2 receptor antagonists
Cole, Andrew G.
Stroke, Ilana L.
Qin, Lan-Ying
Hussain, Zahid
Simhadri, Srilatha
Brescia, Marc-Raleigh
Waksmunski, Frank S.
Strohl, Barbara
Tellew, John E.
Williams, John P.
Saunders, John
Appell, Kenneth C.
Henderson, Ian
Webb, Maria L.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5420 - 5423

← 1 2 3 4 5 →